v3.25.2
Consolidated balance sheets - USD ($)
$ in Millions
Jun. 30, 2025
Dec. 31, 2024
Non-current assets [abstract]    
Property, plant and equipment $ 10,380 $ 9,458
Right-of-use assets 1,446 1,415
Goodwill 25,553 24,756
Intangible assets other than goodwill 29,240 26,915
Investments in associated companies 92 119
Deferred tax assets 5,202 4,359
Financial assets 2,069 2,015
Other non-current assets 4,474 3,505
Total non-current assets 78,456 72,542
Current assets [abstract]    
Inventories 6,307 5,723
Trade receivables 9,056 7,423
Income tax receivables 120 133
Marketable securities, commodities, time deposits and derivative financial instruments 344 1,998
Cash and cash equivalents 6,656 11,459
Other current assets 3,456 2,968
Total current assets 25,939 29,704
Total assets 104,395 102,246
Equity [abstract]    
Share capital 766 793
Treasury shares (33) (53)
Reserves 41,252 43,306
Equity attributable to Novartis AG shareholders 41,985 44,046
Non-controlling interests 69 80
Total equity 42,054 44,126
Non-current liabilities [abstract]    
Financial debts 22,470 21,366
Lease liabilities 1,594 1,568
Deferred tax liabilities 2,321 2,419
Provisions and other non-current liabilities 4,242 4,075
Total non-current liabilities 30,627 29,428
Current liabilities [abstract]    
Trade payables 4,506 4,572
Financial debts and derivative financial instruments 8,314 8,232
Lease liabilities 259 235
Current income tax liabilities 2,826 1,599
Provisions and other current liabilities 15,809 14,054
Total current liabilities 31,714 28,692
Total liabilities 62,341 58,120
Total equity and liabilities $ 104,395 $ 102,246